A retrospective analysis of treatment responses of palmoplantar psoriasis in 114 patients

Abstract

Although the success rates appeared to be high, the high number of patients who required multiple systemic agents emphasized the fact that localized forms of psoriasis were resistant to therapy.

Pustulosis palmoplantaris is a disease distinct from psoriasis

“…The effect of colchicine and topical PUVA was unclear. In a retrospective analysis of treatment responses in patients with PPP, only 17 out of 62 patients showed marked improvement to topical treatments, which suggests that PPP should be regarded as a systemic disease with localized manifestation (23). Anti-TNF-a treatment is disappointing (24)(25)(26)(27)(28)(29).…”

Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate‐to‐severe plaque psoriasis and non‐pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER‐1, UNCOVER‐2 and UNCOVER‐3)

“…[1][2][3] These patients may have localized palmoplantar psoriasis [3][4][5] or generalized psoriasis in addition to the palms and soles. [1][2][3] These patients may have localized palmoplantar psoriasis [3][4][5] or generalized psoriasis in addition to the palms and soles.…”

Efficacy of adalimumab across subgroups of patients with moderate‐to‐severe chronic plaque psoriasis of the hands and/or feet: post hoc analysis of REACH

“…Published information related to specific treatment of hand and/or foot psoriasis focuses mainly on palmoplantar psoriasis. Although topical therapies, including corticosteroids, retinoids, calcipotriol, salicylic acid, and coal tar, are widely used, palmoplantar psoriasis is often resistant, and prolonged corticosteroid use can have undesirable side‐effects . Common light therapies, including topical psoralen plus long‐wave ultraviolet A (PUVA), broadband ultraviolet B, and narrowband ultraviolet B (NB‐UVB), have also been used, but published, definitive conclusions about the effectiveness of NB‐UVB on localized psoriasis are lacking .…”

“…These include PUVA with oral psoralen, methotrexate, cyclosporine, and retinoids; however, adverse effects can limit long‐term use in patients with psoriasis of the hands and/or feet . Patients with localized psoriasis may need multiple treatment agents, which include a combination of topical and systemic medications, during the course of disease to achieve treatment benefit . Biologics approved for the treatment of chronic plaque psoriasis have also been used successfully to treat hand and/or foot psoriasis, although none are currently approved specifically for this condition, and most of the evidence is limited to small clinical studies and case reports …”